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SHORT COMMUNICATION
Cyclosporin A and its analogues as modifiers of adriamycin and
vincristine resistance in a multi-drug resistant human lung cancer cell line
P.R. Twentyman', N.E. Fox' & D.J.G. White2
1Medical Research Council Clinichl Oncology and Radiotherapeutics Unit; and 2University of Cambridge, Department of
Surgery, Hills Road, Cambridge, UK.
The problem of pleiotropic drug resistance in cancer Adriamycin (ADM, Farmitalia) and vincristine (VCR, Eli
chemotherapy may be tackled in a number of ways. One of Lilley) were dissolved in sterile distilled water and added to
these involves the use of additional chemical agents 5 ml of growth medium in a volume of 50 ul. Cyclosporins
(resistance modifiers) which partially or fully restore (Cs) A, C, G and H were kindly supplied by Sandoz Ltd
cytotoxic drug sensitivity to resistant cells. Among agents (Basle). The structures of these compounds are shown in
shown to possess this property are calcium transport Figure 1, and their antifugal and immunosuppressive
blockers (e.g. verapamil) (Tsuruo et al., 1981, 1982, 1983; properties summarised in Table I. The cyclosporins were
Slater et al., 1982; Twentyman et al., 1986a and calmodulin initially dissolved in absolute ethanol. They were then diluted
inhibitors (e.g. trifluoperazine) (Tsuruo et al., 1982, 1983). It 1:10 in medium and finally added to 5ml of growth medium
has recently been shown that the immunosuppressive drug, in a volume of 50p1, thereby producing a final ethanol
cyclosporin A, binds to calmodulin (Colombani et al., 1985), concentration of 0.1%. This concentration of ethanol does
can potentiate the effects of adriamycin and etoposide not affect cell growth or drug sensitivity.
in L1210 cells (Osieka et al., 1986), and is also able to Typical response data for H69/P and H69/LX4 cells
function as a modifier of resistance to daunorubicin and treated with ADM in the presence or absence of CsA are
vincristine in Ehrlich ascites carcinoma in vivo and in acute shown in Figure 2. Data from several experiments where
lymphatic leukaemia in vitro (Slater et al., 1986a,b). In this ADM was combined with CsA at a dose of 5pugml-I are
paper we describe studies carried out using a multi-drug shown in Table II and data for VCR combined with CsA in
resistant variant of a human small cell lung cancer line. The Table III. It can be seen that the addition of CsA at a dose
ability of cyclosporin A and a number of analogues to of 5jugml-1 led to a small increase in the sensitivity of
overcome resistance to adriamycin and vincristine is H69/P to both cytotoxic drugs, whereas a very large increase
investigated. in the sensitivity of H69/LX4 cells was seen. Sensitisation of
The derivation and characteristics of a multi-drug resistant H69/LX4 cells to ADM is clearly dependent upon the dose
variant (NCI-H69/LX4) of the human small cell lung cancer of CsA (Table II) but some sensitisation was still seen at
line NCI-H69/P have been previously described (Twentyman 0.5-1 4ugml1-I CsA.
et al., 1986b). The variant line was obtained by growth of Cyclosporin A
cells in vitro in increasing concentrations of adriamycin. The
cells grow as free-floating aggregates in RPMI 1640 medium 1 2 3 4
supplemented with 10% foetal calf serum (both Gibco C9 - ABU - SAR- MELEU
Biocult Ltd). The aggregates may be reduced to a single cell
suspension using a 15min incubation with trypsin (0.4%)
Drug sensitivity was tested by the inhibition of growth of 11 MEVAL VAL 5
the cells during continuous drug exposure as previously
described (Twentyman et al., 1986b). The assay therefore tV includes a measure of combined cytotoxic and cytostatic MELEU-MELEU*-ALA4 ALAo- MELEU
effects. Tissue culture grade petri dishes (6cm diameter,
Falcon Plastics) were inoculated with 2 x l05 cells (either 10 9 8 7 6
H69/P or H69/LX4) in 5ml of medium on day 0 and drugs Cyclosporin C 2 = THR
added immediately. After 6 days (H69/P) or 7 days
(H69/LX4) a count of total phase contrast viable cells per Cyclosporin G 2 = L-NORVAL
dish was carried out using haemocytometer counting or a Cyclosporin H 11 = D-MEVAL
total cell count obtained using an electronic cell counter
(Coulter Electronics). A comparison between the two Figure 1 Amino acid sequence of cyclosporins. Redrawn from
counting methods confirmed good agreement. von Wartburg and Traber (1986), 9 is a hitherto unknown
The times for cell counting were chosen as being near to amino acid=[2S, 3R, 4R, 6E]-3-hydroxy-4-methyl-2-methyl the
tie of el ountingrwer chosen
as beng near to amino-6-octenoic acid; ABU=L-a-amino butyric acid; the end of the exponential growth phase for control cells at MEVAL=N-methyl-L-valine; MELEU=N-methyl-L-leucine.
which time the original cell number had increased 10-fold. In
most experiments, two replicate dishes were used in the
control growth and a single dish at each of 6 or 7 different Table I Properties ofcyclosporins
drug doses used to establish the drug response curve. In
experiments where duplicate dishes were used for drug Antifungal Immuno-
treatment groups, close agreement between replicates was Cyclosporin activity suppression
seen. Curves were fitted by eye to the drug response data A + ++
and the values of ID80 (the drug dose required to reduce + +++
final cell number to 20% of control) read from the curves. G + +++
H _
Correspondence: P.R. Twentyman.
Received 16 February 1987; and in revised form, 1 April 1987. From von Wartburg and Traber (1986).56 P.R. TWENTYMAN et al.
Adriamycin (,Lg ml-')
2 0.001 0.01 0.1 1.0 10.0
0
0 0.5 O
.0 v
0
VO 0.2
-c0.1 0
U)
= 0.05 0
a)
Figure 2 Number of cells per dish following continuous incubation with various doses of adriamycin. Solid symbols - parent line
NCI-H69/P; open symbols
' resistant line NCI-H69/LX4. Controls: 0, 0 in presence of cyclosporin A (1 igml- ) A; 2pgml1,
V7; 5gml-1, 0, M.
Table II Effect of cyclosporin A upon resistance of NCI-H69 Table III Effect of cyclosporin A upon resistance of NCI-H69 cells
cells to adriamycin to vincristine
Dose of H69/P H69/LX4 Dose of H69/P H69/LX4
CsA CsA
(,ugml-) ID80u(gml-1) SR 1D80(Y1gml1) SR RF (ugml-1) 1D80(pgml-1) SR ]D80(pgmV1_) SR RF
0 0.0063 1.0 0.42 1.0 67 0 0.0010 1.0 2.4 1.0 1700
5 0.0045 1.4 0.022 19.1 4.9 5 0.00045 2.2 <0.018 > 133 <40
0 0.0031 1.0 0.27 1.0 78 0 0.0014 1.0 1.7 1.0 1200
5 0.0023 1.3 <0.011 >24.5 <4.8 5 0.00065 2.1 0.0080 212 12.3
0 0.0055 - 0.80 1.0 145 0 0.0010 1.0 0.90 1.0 900
0.5 - - 0.36 2.2 - 1 0.00068 1.5 >0.20 <4.5 >290
1 - - 0.21 3.8 - 5 0.00048 2.1 0.0095 95 19.8
2 - - 0.22 3.6 -
5 - - 0.012 67 - 0 - - 1.6 1.0 -
0.5 - - 1.2 1.3 -
0 0.016 1.0 > 1.0 1.0 >63 1 - - 0.55 2.9 -
1 - - 0.82 > 1.2 - 2 - - 0.25 6.4 -
2 - - 0.19 >5.2 - 5 - - 0.003 470
5 0.011 1.5 0.032 >31 2.9
0 0.0017 1.0 2.1 1.0 1240
ID80 =dose of drug to reduce final cell count to 20% of 0.5 - - 2.1 1.0
control. 1 - - 2.0 1.1
ID80 in absence of CsA 2 - - 1.1 2.0
SR (sensitisation ratio)= 5 0.00066 2.6 0.026 81 39
ID80 in presence of CsA
ID80 for H69/LX4 For definitions of ID80, SR, RF see Table II.
RF (resistance factor)=--------
ID80 for H69/P
Sensitisation of H69/LX4 to VCR (Table III) was also Table IV Effect of different cyclosporins upon resistance of
seen at 1 jugml -1 of CsA but the effect increases NCI/H69 cells to adriamycin
dramatically only between 2 and 5,ugml m 1. H69P H69/LX4
The ability of CsA analogues to overcome ADM Cyclosporin H
resistance is shown in Table IV. Cyclosporin G was at least Dose ID80 ID80
as active as CsA whilst Cyclosporin C showed less activity at Cyclosporin (ugml-1) (pgml-U) SR (ugml-U) SR RF
5ygml-1. Cyclosporin H showed relatively little ability to
modify ADM resistance even at a dose of I0ygml-1. - 0 0.012 1.0 1.6 1.0 133
It should be noted that there is a degree of inter- A 5 0.011 1.1 0.031 52 2.8
experiment variability in absolute values of ID80. For C 5 0.012 1.0 >0.10 <16 >8.3
example, the ID80 of ADM alone in line H69/P in the 6 H 5 0.009 1.3 0.68 2.4 76
experiments shown in Tables II and IV varies by a factor of
5. We believe that this variability is contributed to by the _ 0 0.015 1.0 3.2 1.0 213
relative wide spacing of drug doses used (2 fold increments) A 5 0.017 0.9 0.12 27 7.0
and probably also the recent culture history of the cells used C 5 0.015 1.0 >0.4 <8 >27.0
to set up individual experiments. G 5 0.015 1.0 0.033 97 2.2
These results confirm, in a human small cell lung cancer H 5 0.0095 1.6 2.8 1.1 294
line, the observations reported by Slater et al., (1986a, b) that_0_ _ 1. 10
CsA is a highly effective agent in modifying cellular A 5- - 0.023 61 -
resistance to anthracyclines and VCR. We have also shown H 2 - - 0.90 1.6 -
that analogues of CsA have a range of abilities to modify H 5 - - 0.72 1.9 -
resistance. Our studies indicate that there is a clear dose- H 10 - - 0.54 2.6 -
response relationship between CsA dose and the extent of
modification of ADM and VCR resistance. Some effect can Fordefinitions of ID80, SR, RF see Table II.CYCLOSPORIN A OVERCOMES MULTI-DRUG RESISTANCE 57
be seen at 0.5-1.0ygml-1 of CsA, but it requires 5pgml-P
to reduce the resistance factor by a factor of 20. Our
previous studies using verapamil have shown that a
verapamil dose of 6.6pM (3.3 jgml-1) is required to
produce a similar modification of ADM resistance in
H69/LX4 (Twentyman et al., 1986a). The maximum
clinically achievable plasma concentration of verapamil
without excessive toxicity is 1-2jgml-I (Rogan et al., 1984),
and peak CsA concentrations of 1-2jgml-1 are observed
following immunosuppressive administration (Kahan et al.,
1983). It would therefore appear that CsA is approximately
an equal candidate to verapamil for clinical use judged solely
on this basis. Examination of the resistance-modifying
properties of the 3 CsA analogues indicates a close
correlation with their immunosuppressive efficiency. If both
of these functions are dependent upon the ability of
cyclosporins to inhibit calmodulin acitivity then this is the
result that would be expected. Other factors could, however,
be involved such as the ability of different cyclosporins to
enter the cell. A quite different mechanism of resistance
modification has, on the other hand, been proposed by
Slater et al. (1986b) who suggests that CsA may promote
cytotoxic drug action at the membrane level by altering the
biophysical properties of the plasma membrane. Studies of
the effects of cyclosporins upon the cellular pharmaco-
kinetics of ADM and VCR currently in progress in our
laboratory should help to elucidate the mechanism of
sensitisation.
The adminstration of an immunosuppressive agent to a
cancer patient in the hope of overcoming cytotoxic drug
resistance is clearly problematic. It is important to determine
if analogues of CsA exist which are able to act as resistance
modifiers in the absence of immunosuppressive properties.
We are currently investigating a range of, additional
analogues which should help to clarify the relationship
between these properties.
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